Navigation Links
Dr. Richard M. Soll Joined WuXi PharmaTech (NYSE: WX) as VP of Medicinal Chemistry
Date:7/13/2008

SHANGHAI, China, July 14 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that Dr. Richard M. Soll has joined WuXi PharmaTech as Vice President of Medicinal Chemistry.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

As a pharmaceutical veteran, Dr. Soll brings over 25 years of scientific experience and proven leadership capability to his new role in WuXi. Prior to joining WuXi, Dr. Soll worked at TargeGen Inc., a San Diego based biotechnology company, as Vice President of Research and Development and Chief Scientific Officer from March 2003 to March 2008. Before joining TargeGen, Dr. Soll held senior positions with increasing responsibilities at Ontogen Corporation and 3-Dimensional Pharmaceutical, Inc.

Dr. Soll is well recognized and respected for his scientific acuity from the academic and industry circles. Amongst his most recent achievements are first-in-class drug development nomination candidates and clinical development drugs for potential treatment for cancer, thrombosis, ocular disease, inflammation, edema and myeloproliferative disorders.

As the Vice President of Medicinal Chemistry Dr. Soll will help the company to expand and strengthen its medicinal chemistry services platform. Dr. Soll will report directly to Dr. Shuhui Chen, Chief Scientific Officer of WuXi PharmaTech.

"I am very excited to welcome Dr. Soll on board to lead and expand our already strong medicinal chemistry unit," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "Previously a customer of WuXi, Rich has a unique perspective on how to maximize service value creation for clients. His broad experience in the pharmaceutical industry and proven track record as a leader make him an ideal fit for the organization. I am confident that under his leadership our medicinal chemistry service capability will be stronger and further integrated with those of other services."

Dr. Soll received his B.S. in Chemistry from the University of Massachusetts, Massachusetts and his Ph.D. in Chemistry from Dartmouth College, New Hampshire. He was also a chemistry post-doctoral fellow at Harvard University with Professor E. J. Corey.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Sherry Shao

Tel: +86-21-5046-4002

Email: pr@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cohera Medical Names Richard L. Wonsettler as Companys First CFO
2. AST Awards Richard N. Fine, M.D. 2008 Ernest Hodge Distinguished Achievement Award
3. Chicago Mayor Richard M. Daley to Address the 7th Annual Compliance and Ethics Institute
4. MultiVu Video Feed: Richard Simmons and Ocean Spray Team-Up to Solve
5. Stop Obesity Alliance, Chair Dr. Richard H. Carmona, National Opinion Research Center Reveal Findings of Survey Showing Employer Concern About Health, Financial Costs of Obesity
6. Veterans Honor Dr. Richard Merkin During Research Week
7. Agendia Appoints Oncologist Richard A. Bender as Vice President and Chief Medical Officer
8. Richard T. Clark Elected PhRMA Board Chairman
9. Danny Calegari Appointed the Richard Merkin Distinguished Professor of Mathematics at the California Institute of Technology
10. Kevin Richardson Named Vice President, Sales, National & Multi-State Business for Kaiser Permanente
11. AACN Applauds Senator Richard Durbin for Introducing the Troops to Nurse Teachers Act of 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional Squash ... has enlisted New York City-based sports and entertainment marketing firm Leverage Agency as ... opportunities for the Professional Squash Association (PSA), which includes first-time ever title sponsorship, ...
(Date:3/29/2017)... ... ... Sublime Naturals and its founder, Kathy Heshelow, are big fans of Turmeric. ... for thousands of years. , "The West has caught on, and has discovered Turmeric, ... Use it For Your Wellness. Overcome Inflammation, Enemy of the Body. " The ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based on research from ... employers face in trying to balance both short-term and long-term benefits demands. ... to the growing complexity, companies are finding that the short-term strategies used to ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... documenting and diagramming network and data center assets and audio-video devices has recently ... request new equipment shapes for free and download shapes and stencils from ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of ... and is touted to be the next revolution in our fight against this complex ... the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... YORK , March 29, 2017 Global intravenous ... US$ 3 billion by 2021, growing at a CAGR of ... iron prescribed by a doctor to treat anemia or other ... iron level in the body. However, in some cases, oral ... the body and intravenous (IV) iron therapy comes into the ...
(Date:3/29/2017)... March 29, 2017  BioSpecifics Technologies Corp. (NASDAQ: ... to develop collagenase based-therapies with a first in ... as XIAFLEX ®  in the U.S. and Xiapex ... a corporate overview at the upcoming 16 th ... 5, 2017 at 8:00 a.m. ET in ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced the ... Therapy Centers & Forecast" report to their offering. ... Proton Therapy Market in Italy ... value in 2016. There are currently three proton therapy centers in ... more patients. In Italy , the first patients were ...
Breaking Medicine Technology: